# 2025 Full Year Earnings Call

## March 2026

---

Today’s Agenda

1. Company Strategy
2. Business Highlights
   - AI Platform
   - Asset Pipeline

---

# Company Strategy

Traditional drug R&D takes >10 years and >$2B*

Probability of Success %  
Cycle time (years)

---

The Locus of AI Acceleration

The real AI impact is between Target Discovery and Preclinical Candidate (PCC),  
beyond PCC stage is heavily regulated and standardized timeline.

---

Evaluating AIDD Companies
Metrics to evaluate an AIDD company: The Potential → The Proof

- AI Productivity Index
- Algorithm Patents
- Compute Power

Insilico Medicine Stats
- 12-18 months Average time to PCC
- $3-5M Average cost to PCC

---

Leveraging the Flywheel Effect to Position Our AI Platform at the Forefront

### PHARMA.AI Software Platform

Continuous improvement and expansion on capabilities and accuracy of PandaOmics, Generative Chemistry and AIchemistry etc.

**2025**
- Launched Nach01, MDFlow, MoISpace etc.
- Launched Model Training, Retrosynthesis, Generative Biologics, DORA etc.

**2024**
- Generated 1000+ benchmarks during PCC development.

Drug Discovery and Development
- Completed 1 Phase IIa trial
- 2 Phase II trial ongoing
- 7 Phase I trial ongoing

---

AI-based Drug Discovery: Greater Novelty, Lower Cost, Faster Pace, and Higher Success

Delivering high-quality, highly novel PCC in significantly reduced time and at lower cost by leveraging AI early in the generative phase to eliminate toxic or unstable compounds before physical synthesis.

---

# Our Pipeline Targets Found in Aging Gene Sets and Aging Clocks

|                | Fibrosis | Oncology/IO | Immunology/IBD | Metabolic | CNS | Cardiovascular/CKD |
|----------------|----------|-------------|----------------|-----------|-----|--------------------|
| **TNIK**      | ●        | ○           |                | ○         | ○   | ○                  |
| **PHD1/2**    |          |             | ●              | ○         |     | ●                  |
| **QPCTL**     |          | ●           |                |           |     | ○                  |
| **NLRP3**     |          | ○           | ●              | ○         | ●   |                    |
| **TEAD**      | ○        | ●           |                | ○         |     | ○                  |

---

# Business Highlights

### Pharma.AI – Continued Innovation and Upgrades

Delivered strong software revenue momentum and transformative advancements in Pharma.AI platform.

Major transformative advancements in 2025 and YTD 2026.

---

Pipeline Momentum – New PCC Nomination Fuel Growth & Clinical Progresses Build Confidence

- 6 PCC Nominated
  - ISM3830 (CBLB)
  - ISM5059 (NLRP3)
  - ISM0676 (GIPR)
  - ISM6166 (Pan-KRAS)
- Pipeline: 
  - Undisclosed (Nav1.8)
  - Undisclosed (GLP-1R)
- Clinical Validation: Completed first-in-patient dosing in Ph1 trial for MEN2501/ISM9682 (KIF18A)
- ISM8969 (NLRP3): Received IND approval from FDA for Ph1 trial.

---

# AI Platform

### Science MMAI Gym: Boosting Biological and Chemical Intelligence

- 6 Scientific Domains: Chemistry, Biology, Clinical, Aging/Longevity, Materials Science, Agriculture.
- 500M+ Data Samples across diverse curated data sources.

### Foundation Model Training Routine

Baseline Performance Science Benchmarks across all therapeutic areas.

---

# Asset Pipeline

~30 Asset Pipeline Discovered from Our Generative AI Platform with an Asset Most Advanced Globally among Peer Companies

| Stage of Development   |                  |                |              |                |                |               |               |               |               |               |
| ---------------------- | ---------------- | -------------- | ------------ | -------------- | ---------------- | ------------- | ------------- | ------------- | ------------- | ------------- |
| **Target**            | **Indication**    | **Target Identification** | **Target-to-hit** | **Hit-to-lead** | **Lead Optimization** | **IND-enabled** | **Phase 1**   | **Phase 2**   | **Phase 3**   | **Partners**   |
| TNIK                  | IPF              | China (NMPA)  | China Phase IIa Completed |
| IPF (Inhalable)      | US (FDA)         |                |                |                |                |               |               |               |               |
| IBD                  | China (NMPA)    | Australia & China Phase I Completed |
| PHD1/2               | Anemia of Chronic Kidney Disease | China (NMPA) |                |                |                |               |               |               | Greater China rights out-licensed to TaiGen |
| USP1                 | BRCA-mutant Cancer | US (FDA)      |                |                |                |               |               |               | POXUN PHARMA |
|  ...                  |                  |              |              |                |                |               |               |               |               |               |

---

# Business Model

**Multi-Pronged Revenue Generating Business Model for Long-term Growth**

- Generated ~30 asset pipeline.
- 10+ out-licensing or collaboration deals with total contract value of >US$4.6 billion.
- Collaborated with 75 customers for drug discovery business in 2025.

---

# Financials

**Income Statement and Cash Position**

|                         | Year ended December 31 |                   |
|-------------------------|-------------------------|-------------------|
|                         | 2024 USD'000            | 2025 USD'000      |
| Revenue                 | 85,834                  | 56,239            |
| Cost of revenue         | (8,257)                | (10,391)          |
| Gross Profit            | 77,577                  | 45,848            |
| Selling and marketing expenses | (5,532)         | (6,328)           |
| Research and development expenses | (91,895)      | (81,379)          |
| Administrative expenses  | (17,487)               | (17,416)          |
| Loss before tax         | (16,935)               | (352,256)         |

---

**2026 Key Milestones Across both the Platform and Therapeutic Pipeline**

- ISM6331 (TEAD) preliminary safety, efficacy, and biomarker data from Ph1 trial.
- Rentosertib (Inhalable) IND approval for the treatment of IPF in China.
- Continue to execute MMAI Gym collaborations.
- Continue to achieve new BD deals.